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Abstract
Background: One of the most anticipated, but potentially serious complications during or after
surgery are bleeding events. Among the many potential factors associated with bleeding
complications in surgery, the use of bovine thrombin has been anecdotally identified as a possible
cause of increased bleeding risk. Most of these reports of bleeding events in association with the
use of topical bovine thrombin have been limited to case reports lacking clear cause and effect
relationship determination. Recent studies have failed to establish significant differences in the rates
of bleeding events between those treated with bovine thrombin and those treated with either
human or recombinant thrombin.
Methods: We conducted a search of MEDLINE for the most recent past 10 years (1997–2007)
and identified all published studies that reported a study of surgical patients with a clear objective
to examine the risk of bleeding events in surgical patients. We also specifically noted the reporting
of any topical bovine thrombin used during surgical procedures. We aimed to examine whether
there were any differences in the risk of bleeds in general surgical populations as compared to those
studies that reported exposure to topical bovine thrombin.
Results: We identified 21 clinical studies that addressed the risk of bleeding in surgery. Of these,
5 studies analyzed the use of bovine thrombin sealants in surgical patients. There were no
standardized definitions for bleeding events employed across these studies. The rates of bleeds in
the general surgery studies ranged from 0.1%–20.2%, with most studies reporting rates between
2.6%–4%. The rates of bleeding events ranged from 0.0%–13% in the bovine thrombin studies with
most studies reporting between a 2%–3% rate.
Conclusion: The risk of bleeds was not clearly different in those studies reporting use of bovine
thrombin in all patients compared to the other surgical populations studied. A well-designed and
well-controlled study is needed to accurately examine the bleeding risks in surgical patients treated
and unexposed to topical bovine thrombin, and to evaluate the independent risk associated with
topical bovine thrombin as well as other risk factors.
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Background
It is well accepted that there are both risks and tremen-
dous health benefits associated with surgical procedures
of all types. Surgical risks vary in severity and type and are
driven by a complex mix of factors including surgical fac-
tors (e.g., type of surgery), surgeon characteristics (e.g.,
experience with conduction specific procedures), patient
factors (age, gender, prior history of surgery, prior history
of adverse events, comorbidities, etc.), other treatment
factors (e.g., use of anticoagulants), and random chance.
One of the most anticipated, but potentially serious com-
plications in surgery is the risk of bleeding events. Among
the many potential causes of bleeding complications in
surgery, the use of bovine thrombin has been anecdotally
identified as a possible cause of increased bleeding risk.
Most of these reports of bleeding events in association
with the use of topical bovine thrombin are case reports
and small case series from which no clear cause and effect
relationship could be established [1-16]. A more recent
study failed to establish any significant differences in the
rates of bleeding events between those treated with bovine
thrombin and those treated with either human or recom-
binant thrombin [17].
Bovine thrombin has been used as a commercial hemo-
stat for more than 60 years, and whether used alone or in
combination with other clotting agents, it effectively helps
to control surface bleeding in a variety of cardiovascular,
vascular, neurological, orthopedic, transplant, and gyne-
cologic surgeries [5,18,19]. Although bovine thrombin is
often used as a hemostat in surgical procedures, only a few
published studies have quantified the safety and efficacy
of bovine thrombin in surgery. It is well documented in
recent years that human exposure to bovine thrombin
preparations has been associated with an allogentic anti-
bovine response, as well as cross reactivity to human coag-
ulation factors. High titers of antibodies directed against
bovine clotting factors seem well documented as an
immediate and common consequence of surgery and as a
lifetime risk for those patients who receive multiple expo-
sures of exogenous factors [9,20]. However, the clinical
significance of this immunization on resulting adverse
events is not clear or well documented. The adverse events
of most interest, theoretically and clinically in surgery and
treatment with bovine thrombin, are major bleeding
events. If the antibody development associated with
bovine thrombin exposure were to have an impact on the
incidence of any adverse events, the most likely outcome
would be the risk of major bleeds. Because the expected or
background risk of bleeding events in surgery is not well
documented, especially for surgery during which bovine
thrombin is utilized, this literature review intends to
examine and report the incidence of major bleeding
events in published studies of surgery, as well as those spe-
cifically reporting bovine thrombin exposure and to deter-
mine whether the rates are notably different.
Methods
We conducted a literature search of MEDLINE (via
PubMed) for English language studies published within
the past 10 years (1997–2007). We conducted our search
of MEDLINE using a combination of text terms and Med-
ical Subject Headings (MeSH) terms focused on surgery
and bleeding events. We reviewed all the abstracts and
retrieved all papers that met our eligibility criteria. We
included all published studies that reported a study of sur-
gical patients with a clear primary or secondary objective
to examine and/or quantify the risk of bleeding events in
that surgical population. For review articles that addressed
this issue, we examined the references, retrieved all poten-
tially eligible articles, and reviewed those as well.
Study inclusion and exclusion criteria are detailed below:
Exclusion criteria
￿ Letters, editorials, news, case-reports, commentaries,
and reviews
￿ Animal or in vitro studies
￿ Language other than English
￿ Study participants who were not undergoing surgery
￿ Studies of organ transplants
￿ Studies without a primary/secondary objective of exam-
ining or quantifying the risk of bleeding events in surgical
patients
Inclusion criteria
￿ Studies published from 1997–2007
￿ English language
￿ Studies of surgical patients with a clear primary or sec-
ondary objective of examining or quantifying the risk of
bleeding events
Additionally, we conducted a secondary search using text
and MeSH terms to identify surgical studies of bovine
thrombin. We expected the yield of this search to be much
smaller, so these studies were not required to have a pri-
mary/secondary objective of studying the risk of bleeding
events, rather all studies that reported bleeding events
were included. We also applied the same inclusion/exclu-
sion criteria regarding publication date, English language,
and organ transplant studies to the bovine thrombin stud-
ies.Patient Safety in Surgery 2008, 2:5 http://www.pssjournal.com/content/2/1/5
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We reviewed and summarized all studies regarding sur-
gery type, sample size, geographic location, study design,
definition of bleeding events, and risk of bleeding events.
Incidence of bleeds in surgery studies
We identified 16 studies that met our inclusion criteria,
which are presented in Additional file 1, Table 1 [21-36].
Seven of these studies were cardiovascular surgery studies
[25,27,28,31,32,35,36], three were pancreatic surgery
[21,24,29], and the others included major abdominal sur-
gery [23], major orthopedic surgery [33], non-cardiac gen-
eral surgery [34], laparoscopic cholecystectomy [26],
prostatic resection [22], and laparoscopic and thoraco-
scopic surgery [30]. Seven of the studies included more
than 1,000 patients[23,24,26,28,30,31,33]. Three studies
were based in the United States, nine were based in
Europe, and one each was based in Canada, Israel, Aus-
tralia, and India.
Most of the studies had a very detailed definition of bleed-
ing events, while several just reported specific events such
as re-exploration for bleeding or delayed massive hemor-
rhage. There were no standardized definitions for bleed-
ing events, major bleeds, etc., employed across these
studies. The rates of bleeds ranged from 0.1% for fatal
bleeds in orthopedic surgery [33] to 20.2% for bleeding
complications in cancer patients undergoing pancreati-
coduodenectomy [21]. The incidence of bleeding events
in coronary artery bypass graft (CABG) patients was very
similar across the six studies of CABG patients
[27,28,31,32,35,36], ranging from 3.1% [28] to 5.4%
[35], with the other studies reporting rates between 4%–
4.6%. Three of the CABG studies reported rates of bleed-
ing events to be between 4.0%–4.8% [27,31,32]. Those
same CABG studies also showed an increased risk of
bleeds with pre-operative aspirin use (7.8% risk of bleeds;
[36]) and clopidogrel (8% risk with clopidogrel use
within three days prior to surgery). The rates of bleeding
events are presented in Additional file 1, Table 1 and show
that most studies report a rate of 2.6%–4%.
The three pancreatic surgery studies showed a wide range
of bleed rates from 2.3% for delayed massive hemorrhage
[24] to 8.8% with at least one bleeding event [29], and
20.2% in the cancer patients [21]. The study reporting
8.8% risk of bleed events also reported a 47% fatality rate
among those patients experiencing hemorrhage.
The prostatic resection study of 826 patients comparing
two approaches found a 3.6% risk of delayed hemorrhage
and a 4%–4.8% risk of total bleeds depending on the sur-
gical approach [22]. A national study of laparoscopic
cholecystectomy patients from Hungary reported a 1.44%
risk of postoperative bleeds via a hospital survey of bleed-
ing events [26]. A national registry of laparoscopic surgery
patients from Switzerland also reported a lower rate of
bleeding events with a 3.3% incidence of major bleeds
[30]. A randomized trial of heparin thromboprophylaxis
for major abdominal surgery in the United Kingdom
found rates of total bleeds of approximately 11% in both
the low molecular weight heparin and standard heparin
groups with about an 8% incidence of major bleeds. The
risk of bleeds in this study during the operation (5.8%)
appeared to be similar to the rate of bleeds and post-oper-
atively (6.5%) [23].
A study of non-cardiac general surgery patients in the
Netherlands reported a 2.6% risk of all bleeds and a 0.9%
risk of major bleeds [35]. A study of major orthopedic sur-
gery in the United States reported an overall 2.6% risk of
major bleeds and a 0.7% risk of re-operation for bleeding
[33]. The study also noted that the rates of major bleeds
varied by surgery type with 4.9% in total hip replacement,
1.3% in major knee surgery, and 2.8% in hip fracture
repair. They also reported that factors such as older age,
male gender, and presence of comorbid hepatic/renal dis-
orders significantly increased the risk of a major bleed
event.
None of these studies of surgical patients reported
whether any or all of the patients in the study received
treatment with any bovine thrombin-containing prod-
ucts.
Incidence of bleeds in bovine thrombin surgery 
studies
Our review of the literature identified five studies that
reported the risk of bleeds in a surgical population treated
with bovine thrombin [5,9,17,37,38]. The studies ranged
in size from 21 patients [37] to 411 patients [17], and are
summarized in Additional file 1, Table 2. The rates of
bleeding events ranged from 0.0% [37] to 13% (human
thrombin treatment arm; [17], with most studies report-
ing between a 2%–3% rate of bleeding events. The rates
are also displayed in Additional File 1, Table 2, showing
that average rate of bleeds is in the range of 2%–3.5%,
similar to what was seen in the other published surgical in
Additional file 1, Table 1.
A study of 21 cardiothoracic surgical patients exposed to a
fibrin glue of bovine fibrinogen and bovine thrombin
during surgery were tested for anti-bovine fibrinogen titers
prior to surgery and followed for 233 days [37]. All
patients demonstrated elevated anti-bovine fibrinogen
antibodies. When nine patients with the highest anti-
bovine fibrinogen were retested, they displayed high titers
for bovine thrombin and human thrombin as well. How-
ever, none of the 21 patients developed postoperative
bleeding complications, including those with initially
high fibrinogen titers. A second study was conducted byPatient Safety in Surgery 2008, 2:5 http://www.pssjournal.com/content/2/1/5
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Dorion et al [5] that examined stored blood samples and
hospital records and identified 120 patients previously
exposed to bovine thrombin. Of these patients who could
be identified from medical records, 102 had been exposed
once to bovine thrombin and 18 had been exposed mul-
tiple times. The study also included 114 patients who had
been unexposed to bovine thrombin. The study found
that of the patients who had been exposed to bovine
thrombin, 10% had antibodies to bovine thrombin; in
patients singly exposed, the rate was 5%; and in patients
exposed multiple times, the rate was 39%. The incidence
of serious bleeds in bovine-thrombin exposed patients
was 1.7% (two of 120 patients) of the total exposed
patients while it was higher (17%; two of 12 patients) in
those patients specifically who had antibodies to bovine
thrombin. The number of patients with bleeding events
was notably low and the subgroup of patients with anti-
bodies is too small to draw any firm conclusions.
A study of 151 surgery patients exposed to bovine
thrombin was conducted by Ortel et al [9], which pro-
vided detailed information on the frequency and types of
adverse events occurring in surgical patients (109 CABG
patients and 42 valve surgery patients) exposed to bovine
thrombin. Of the 151 total surgery patients, 7.3% devel-
oped excessive postoperative bleeding or had a reopera-
tion for bleeding, 3.3% required transfusion support after
postoperative Day 2, and 3.3% experienced gastrointesti-
nal bleeding. When examining the role of risk factors in
this patient population, it was determined that prior sur-
gical procedure, increased thrombin exposure during the
study, postoperative elevated levels to human coagulation
proteins, and postoperative abnormal coagulation study
results were not significantly associated with an increased
risk of adverse events. While it was determined that hav-
ing preoperative elevated antibody levels to two or more
bovine proteins was a significant risk factor for an incident
adverse event, it was conversely also determined that hav-
ing postoperative elevated antibody levels to two or more
bovine proteins was actually associated with a significant
decreased risk of adverse events.
There were two randomized trials included in the review
that reported complete safety data, including bleeding
complications [17,38]. One study compared FloSeal™ to
another bovine thrombin product called Gelfoam® (both
included thrombin-JMI) in 309 surgery patients who were
randomized to the two treatments during surgery [38].
The study did not compare the rates of safety events across
the two thrombin-treated study groups, but rather
reported the total occurrence of adverse events. In the 309
patients, 2.9% developed excessive post-operative bleed-
ing, 4.9% developed anemia, 0.32% experienced a trans-
fusion reaction, and 0.65% had decreased platelets. The
study found no association between the presence or
absence of bovine antibodies and the occurrence of bleed-
ing complications at the six- to eight-week follow-up.
The second and most recent randomized trial randomized
206 surgical patients to treatment with bovine thrombin
(Thrombin JMI) and 205 patients to treatment with
recombinant human thrombin (rhThrombin). At base-
line, 5% of the patients randomized to receive bovine
thrombin had antibodies to bovine thrombin, while 1.5%
of the patients who received rhThrombin had antibodies
to human thrombin. At the one-month follow-up, 21.5%
of the bovine thrombin group had an antibody elevation;
the rhThrombin group had no new antibody elevations.
However, there were no significant differences in regards
to the incidence of adverse events. In each treatment
group, 99.5% of patients reported some adverse event,
with 22% of the bovine thrombin and 18% of the human
thrombin patients reporting a serious adverse event. There
were 11% of bovine-thrombin treated patients that expe-
rienced a bleeding event compared to 13% of patients
with human thrombin. Rates in this study seemed to be
much higher than other studies, but as indicated by
99.5% of patients being noted to have had an adverse
event, the safety reporting seemed to be very thorough
and may have included a large number of minor adverse
events that would not have been noted in the other pub-
lished surgical studies. It should be noted that the two
randomized treatment arms had comparable rates,
regardless of the higher numerical values of those rates.
Discussion
The rates of perioperative bleeding events in studies of
surgical patients ranged from 0%–11% in patients defi-
nitely exposed to bovine thrombin, with most studies
reporting rates between 2%–3%. The rates for the other
published studies of surgical patients ranged similarly
from 0.1% to just over 20%, with most studies reporting
rates between 2%–5%. The risk of bleeds was not clearly
different in those studies reporting use of bovine
thrombin in all patients compared to the other surgical
populations studied. Due to the lack of reporting in the
general surgery studies, it should be noted that it is possi-
ble that many of the patients in these studies were also
exposed to bovine thrombin products.
It was clear that the rates varied with different patient, sur-
gical, and other risk factors. Several studies clearly noted
that surgical factors such as the type of surgery [33], com-
plexity of surgery [23], and urgency of surgery [28]
affected the risk of bleeding events. Further, patient char-
acteristics such as age, gender, body mass index, comorbid
conditions (e.g., cancer, atrial fibrillation), and treatment
characteristics such as concomitant medications (e.g.,
clopidogrel, warfarin, aspirin) are also associated with
increased risks of bleeds in surgical patients. The studiesPatient Safety in Surgery 2008, 2:5 http://www.pssjournal.com/content/2/1/5
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that included entire populations of patients treated with
bovine thrombin did not appear to demonstrate a higher
rate of bleeds than the other published surgical studies,
although no formal statistical tests were conducted.
Unfortunately, most of the studies examined did not con-
duct comprehensive analyses of multivariate factors in the
examination of the risk of bleeding events in surgery, and
thus many of reported bleeding rates may be confounded
by a variety of risk factors.
Many of the surgical studies included in our comparator
surgical group may have employed the use of bovine
thrombin in several of their previous surgeries. Because
most studies do not routinely report the use of bovine
thrombin in surgery in their publications, there is no way
to confirm. Even if these studies did include bovine
thrombin patients – and it would be expected that they
would because thrombin is such a commonly used prod-
uct in surgery – if bovine thrombin did increase the risk of
bleeding events in surgery, it would be expected that there
would be some indication of higher bleeding rates in the
bovine thrombin studies; which there is not. This expecta-
tion would be to do a comparison of a group of 100%
bovine-thrombin treated patients being compared to a
group with some unknown proportion exposed to bovine
thrombin (but with that proportion clearly being lower
than 100%).
We identified all of the published studies within the past
10 years via our comprehensive search methodology that
had a clear primary or secondary intention of examining
the risk/rate of bleeding events in surgical patients. There
are many additional studies that may provide information
on the risk of bleeding events in surgical patients as a part
of their safety results and conclusions. We did not include
these studies in this review because we felt that the only
way to ensure that the reporting of bleeding events was
complete was to require that the study have this as a clear
primary or secondary objective of the study. Without the
requirement of focused, detailed reporting, we would
have to make assumptions to the completeness of report-
ing and wouldn't be sure whether the three bleeding
events reported in a study were all of the bleeding events,
all of the serious bleeding events, or whether the reporting
was driven by some other factor that would result in a par-
tial reporting of events.
It should be considered that the definitions of a "bleeding
event" differed substantially across studies and that this
may lead to difficulty in comparing the rates across studies
and treatment group and making scientific conclusions.
This is definitely a possibility to explore for more focused
comparisons, but even in the studies that report all bleed-
ing events in the surgical population, the rates were still
comparable to the bovine thrombin groups, if not lower
for bovine thrombin. Prior research has also demon-
strated that study design is an important factor in under-
standing the risk of adverse events, and hence it may be
expected that we may see higher rates of adverse events in
randomized trials due to active surveillance for the event
of interest as compared to retrospective observational
studies where the events only present when symptomatic
[39]. Although this would still apply here, we believe that
this is less of an issue as major bleeding events would be
identified regardless of the study design and/or definition
of bleeding events.
The evidence in this literature review suggests that the
rates of bleeding events in bovine thrombin surgical stud-
ies and other published surgical studies are not notably
different. Unfortunately, this comparison is far from opti-
mal and the results could be driven by a large number of
factors. There are many elements, including definition of
bleeding event, type of surgery, patient factors, and other
risk factors that can influence the risk of bleeding events
in surgical patients. Unless the authors controlled for
these factors in their own original research, it is unlikely
that they can be compared and evaluated retrospectively
from their published work. This indirect comparison of
bovine thrombin treated patients to other surgical
patients provides suggestive evidence, but is limited in its
ability to make definitive conclusions due to the
unknown, but expected inter-study variability. None of
the bovine thrombin surgical studies provided a compara-
ble non-bovine thrombin treatment group from which to
compare, although Chapman et al [17] did compare
bovine thrombin to randomized treatment with
rhThrombin and found no differences. More prospective
studies are needed to accurately estimate the bleeding
risks in surgical patients treated with topical bovine
thrombin and patients not exposed to topical bovine
thrombin, and to establish the risk of bleeding attributed
to topical bovine thrombin and to other identifiable fac-
tors.
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